MGNX PEER ANALYSIS

MacroGenics Inc — metric-by-metric comparison with peers and the industry median

MGNXMacroGenics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
MGNXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
MGNX+241.3%MSB+27.6%RTALB+24.1%TLX-29.5%
Year-to-Date (YTD)
MGNX+192.5%MSB-24.3%RTALB+5.0%TLX+50.7%

Key Metric Comparison

P/E

Lower is better
MGNXMSBRTALB4.89TLXMedian 17.91

ROE

Higher is better
MGNX-140.3%MSB-11.3%RTALB15.1%TLX-1.8%Median -47.5%

Net Margin

Higher is better
MGNX-44.8%MSB-115.3%RTALB136.3%TLX-0.9%Median -125.7%

Revenue Growth

Higher is better
MGNX3.1%MSB410.4%RTALB24.0%TLX56.3%Median 5.1%

All Metrics

Valuation
MetricMGNXMSBRTALBTLXInd. Median
P/E4.8917.91
P/B14.100.616.373.51
EV/EBITDA74.61120.1414.82
P/S1.9031.616.673.2410.89
Financial Health
MetricMGNXMSBRTALBTLXInd. Median
Current Ratio1.901.211.435.90
Debt/Equity172.2%1.2%112.3%10.9%
NetDebt/EBITDA2.320.9013.131.15
Profitability
MetricMGNXMSBRTALBTLXInd. Median
Net Margin-44.8%-115.3%136.3%-0.9%-125.7%
ROE-140.3%-11.3%15.1%-1.8%-47.5%
ROA-31.8%-8.6%13.1%-0.7%-35.8%
EBITDA Margin-32.2%-76.6%9.0%3.0%-105.8%
Growth + Dividend
MetricMGNXMSBRTALBTLXInd. Median
Rev. Growth3.1%410.4%24.0%56.3%5.1%
NI Growth134.0%12.1%
Div. Yield0.0%0.0%0.2%
Payout0.0%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on MGNX

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.